1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin 2010; 60(5):277–300. 2. Ries L, Eisner M, Kosary C, et al., eds.: Cancer Statistics Review, 1975-2002. Bethesda, Md: National Cancer Institute, 2005 3. The Health Consequences of Smoking: A Report of the Surgeon General.(ed 2010/07/30).Atlanta:U.S. Department of Health and Human Services. Centers for Disease Control and Prevention (US); 2004. 4. Hecht S.S. Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention. Lancet Oncol 2002; 3: 461–69. 5. Fong K.M.; Sekido Y.; Gazdar A.F.; Minna J.D. Molecular biology of lung cancer: clinical implications. Thorax, 2003, 58, 892-900. 6. Brenner, H. Long-term survival rates of cancer patients achieved by the end of the 20th century: A period analysis. Lancet 2002, 360, 1131-1135. 7. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in nonsmall cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311:899–909. 8. Le Chevalier T, Belli L, Monnier A, et al. Phase II study of docetaxel (Taxotere) and cisplatin in advanced non small cell lung cancer (NSCLC):an interim analysis. Prog Proc Am Soc Clin Oncol 1995;14:350. 9. NCCN Clinical Practice Guidelines in Oncology. NSCLC. Version I.2013 www.nccn.org 10. Thongprasert S, Sanguanmitra P, Juthapan W, et al. Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy. Lung Cancer 1999;24:17–24. 11. Galán Y, Fernández L, Torres P, García M. Trends in Cuba’s Cancer Incidence (1990 to 2003) and Mortality (1990 to 2007). MEDICC Review. 2009;11(3):19–26. 12. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002;346:92-98. 13. V. Zietemanna, T. Duellb.Prevalence and effectiveness of first-, second-, and third-line systemic therapy in a cohort of unselected patients with advanced non-small cell lung cancer. Lung Cancer2011;73: 70– 77. 14. NSCLC Meta-Analyses Collaborative Group. Chemotherapy in Addition to Supportive Care Improves Survival in Advanced Non-Small- Cell Lung Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data From 16 Randomized Controlled Trials. J Clin Oncol 2008;26:4617-4625. 15. Kelly K, Crowley J, Bunn PA, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: A Southwest Oncology Group trial. J Clin Oncol 2001;19:3210-3218. 16. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000;18:2354-2362. 17. Pujol JL, Breton JL, Gervais R, et al. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol 2005;16:602-610. Epub 2005 Mar 1. 18. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advancedstage NSCLC. J Clin Oncol 2008;26(21):3543-3551. 19. Belani CP, Barstis J, Perry MC, et al. Randomized Trial for Stage IIIB or IV Non–Small-Cell Lung Cancer Using Weekly Paclitaxel and Carboplatin Followed by Maintenance Weekly Paclitaxel or Observation. Journal of Clinical Oncology 21:2933- 2939, 2003. 20. Hannah N, Neubauer M, Ansari R, et al.Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01-24/USO-023. Proc Am Soc Clin Oncol 25,abstr 7512, 2007. 21. Kiura K, Takigawa N, Segawa Y, et al. Randomized phase III trial of docetaxel and cisplatin combination chemotherapy versus mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer: OLCSG 0007. Proc. Amer. Soc. of Clin. Oncol. abstr.7515, 2008. 22. Kelly K, Chansky K, Gaspar L, et al. Updated analysis of SWOG 0023: A randomized phase III trial of gefitinib versus placebo maintenance after definitive chemoradiation followed by docetaxel in patients with locally advanced stage III non –small cell lung cancer. Proc. Amer. Soc. of Clin. Oncol. abstr. 7513, 2007. 23. Gandara D, Chansky K, Albain K, et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol. 15:2004-10, 2003. 24. Huidobro G, Vàzquez S, Làzaro M, et al. Docetaxel (D) and cisplatin (C) induction chemotherapy followed by bi-weekly D with concurrent thoracic radiotherapy for stage III non-small cell lung cancer (NSCLC): A Galician Lung Cancer Group study. Proc. of Amer. Soc. of Clin. Oncol. abstr. 7561, 2008. 25. Brodowicz T, Krzakowski M, Zwitter M, et al. Cisplatin and gemcitabine first line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced NSCLC: A phase III trial. Lung Cancer; 52: 155-163, 2006. 26. Ciuleanu T, Brodowicz T, Belani C, et al. Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: A phase III study. Proc of Amer. Soc. of Clin. Oncol. abstr. 8011, 2008. 27. Westeel V, Quoix E, Moro-Sibilot D, et al. Randomized study of maintenance Vinorelbine in Responders With Advanced Non – Small-Cell Lung Cancer. J Natl Cancer Inst, 97:499-506, 2005. 28. Shepherd F, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095-2103, 2000. 29. Shepherd F, Pereira J, Tudor C, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-32, 2005. 30. Hanna N, Shepherd FA, Fossella FV, Pereira JR, DeMarinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J ClinOncol2004;22:1589–97. 31. Douillard J, Kim R, Hirsh V, et al. Gefitinib versus docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer pre-treated with platinum-based chemotherapy: a randomized, open label Phase III study. J Thoracic Oncology 2:Suppl 4, S305-306, 2007. 32. Vansteenkiste J. Improving patient management in metastatic non-small cell lung cancer. Lung Cancer 2007;57(Suppl. 2):S12–17. 33. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O’Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J ClinOncol 2000;18: 2095–103. 34. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med2005;353: 123–32. 35. Stinchcombe TE, Socinski MA. Maintenance therapy in advanced non-small cell lung cancer: current status and future implications. J Thorac Oncol 2011; 6(1):174–82. 36. Novello et al: Maintenance therapy in NSCLC: why? To whom? , Which agent? .Journal of Experimental & Clinical Cancer Research 30:50.2011: 37. Gerard C, Debruyne C. Immunotherapy in the landscape of new targeted treatments for nonsmall cell lung cancer. Mol Oncol. 2009 Dec;3(5–6):409–24. 38. Pirker R, Periera JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open label randomised phase III trial. Lancet 2009;373:1525-1531. 39. MacKinnon A. C.; Kopatz J.; Sethi T. The molecular and cellular biology of lung cancer: identifying novel therapeutic strategies. British Medical Bulletin, 2010, 95, 47-61. 40. Toyooka S.; Mitsudomi T.; Soh J.; Aokage K.; Yamane M.; Oto T.; Kiura K.; Miyoshi S. Molecular oncology of lung cáncer. Gen. Thorac. Cardiovasc. Surg., 2011, 59, 527-537. 41. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010. 42. Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison offluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression. J Thorac Oncol 2011;6:1359-1366. 43. Rodríguez P. C.; Rodríguez, G.; González, G.; Lage, A. Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small cell lung cancer therapy. Meddic Rev. 2010, 12, 17- 44. Bender A.; Karbach J.; Neumann A.; Jäger D.; Al-Batran S.E.; Atmaca A.; Weidmann E.; Biskamp M.; Gnjatic S.; Pan L.; Hoffman E.; Old L.J.; Knuth A.; Jäger E. LUD 00-009: Phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer. Cancer Immunity 2007; 7:16-24. 45. Vázquez A.M.; Hernández A.M.; Macías A.; Montero E.; Gómez D.E.; Alonso D.F.; Gabri M.R.; Gómez R.E. Racotumomab: an anti-idiotype vaccine related to N-glycolyl- containing gangliosides–preclinical and clinical data. Frontiers in Oncology 2012, 2(10)150 1-6. 46. Luis Corrales-Rodriguez L., Blais N., Soulieres D. Emepepimut-S for non-small cell lung cancer. Expert Opin. Biol. Ther. 2011; 11(8):1091-1097. 47. Quoix E, Ramlau R, Westeel V, Papai Z, Madroszyk A, Riviere A, Koralewski P, Breton J, Stoelben E, Braun D, Debieuvre D, Lena H, Buyse M, Chenard M, Acres B, Lacoste G, Bastien B, Tavernaro A, Bizouarne N, Bonnefoy J, Limacher J. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial. Lancet Oncol 2011; 12: 1125–33. 48. Pirker R, Szczesna V, von Pawel J, et al. FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 26 (May 20 suppl abstr 3), 2008. 49. Sandler A, Gray R, Perry M, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small- cell lung cancer. N Engl J Med 355:2542-2550, 2006. 50. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. AVAiL. J Clin Oncol 27, 1227-1234, 2009. 51. Butts C, Murria N, Maksymiuk A et al, Randomized Phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small cell lung cancer. J Clin Onc 23: 6674-6681, 2005. 52. Fidias PM, Dakhil SR, Lyss AP,et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small cell lung cancer. J Clin Oncol 27:591-598, 2009. 53. Sederholm C, Hillerdal G, Lamberg K et al. Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: The Swedish Lung Cancer Study Group. J Clin Oncol 23:8380–8388, 2005 54. Belani CP, Lee JS, Socinski MA et al. Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer. Ann Oncol 16:1069–1075, 2005. 55. Fossella F, Pereira JR, von Pawel J et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 study group. J Clin Oncol 21:3016–3024, 2003. 56. Ciuleanu TE, Brodowicz T, Belani CP, et al: Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: A phase III study. J ClinOncol 26:426s, 2008 (suppl; abstr 8011) 57. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11: 521–529. 58. Miller VA, O´Connor P, Soh C, et al. A randomized ,double-blind, placebo-controlled,phaseIIIb trial (ATLAS) comparing bevacizumab(B) therapy with or without erlotinib(E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer(NSCLC).J Clin Oncol.2009;27:18s(suppl):abstr LBA8002. 59. Miyake M, Hashimoto K, Ito M, Ogawa O, Arai E, Hitomi S, et al.The abnormal occurrence and the differentiation-dependent distribution of N-acetyl and N-glycolyl species of the ganglioside GM2 in human germ cell tumors. Cancer. 1990;65(3):499-505. 60. Durrant LG, Noble P, Spendlove I. Immunology in the clinic review series; focus on cancer: glycolipids as targets for tumour immunotherapy. Clin Exp Immunol. 2012;167(2):206-15. 61. Wiegandt H. The chemical structures of gangliosides. En: Oettgen HF, Ed. Gangliosides and cancer, VCH Publishers, New York, 1989. 62. Herberman RB. Tumor immunology. JAMA. 1992;268:2935-2939. 63. 50Tsuchida T, Saxton RE, Morton DL, Irie RF. Gangliosides of human melanoma. J Natl Cancer Inst 78:45, 1987. 64. Cazet A, Julien S, Bobowski M, Burchell J, Delannoy P. Tumour-associated carbohydrate antigens in breast cancer. Breast Cancer Res. 2010;12(3):204 65. Marquina G, Waki H, Fernandez LE, Kon K, Carr A, Valiente O, et al. Gangliosides expressed in human breast cancer. Cancer Res. 1996;56(22):5165-71. 66. Estevez F, Carr A, Solorzano L, Valiente O, Mesa C, Barroso O, et al. Enhancement of the immune response to poorly immunogenic gangliosides after incorporation into very small size proteoliposomes (VSSP). Vaccine. 1999;18(1-2):190-7. 67. Mateo C, Moreno E, Amour K, Lombardero J, Harris W, Perez R. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity. Immunotechnology 1997; 3(1):71-81. 68. Astsaturov I, Cohen RB, Harari PM. EGFR-targeting monoclonal antibodies in head and neck cancer. Curr Cancer Drug Targets 2006;6:691-710. 69. Crombet-Ramos T, Rak J, Perez R, Viloria-Petit A. Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody. Int J Cancer 2002;101:567-75. 70. Carr A, Mullet A, Mazorra Z, Vázquez AM, Alfonso M, Mesa C, et al. A Mouse IgG1 Monoclonal Antibody Specific for N-GlycolylGM3 Ganglioside Recognized Breast and Melanoma Tumors. HYBRIDOMA. 2000;19(3):241-247. 71. Blanco R, Quintana Y, Blanco D, Cedeño M, Rengifo CE, Frómeta M, et al. Tissue reactivity of the 14F7 Mab raised against NGlycolylGM3 ganglioside in tumors of neuroectodermal, mesodermal and epithelial origin. Journal of Biomarkers. 2013 72. Blanco R, Blanco D, Quintana Y, Escobar X, Rengifo CE, Osorio M, et al. Immunoreactivity of the 14F7 Mab raised against NGlycolylGM3 ganglioside in primary lymphoid tumors and lymph node metastasis. Patholog Res Int. 2013;2013:920972. Epub 2013 Nov 28). 73. Bada A, Casaco A, Arteaga M, Martinez J, Leon A, Santana E, et al. Toxicity of a GM3 cancer vaccine in Macaca fascicularis monkey: a 12-month Study. Hum Exp Toxicol. 2002;21(5):263-7. 74. Labrada M, Clavell M, Bebelagua Y, León J, Alonso DF, Gabri MR, et al. Direct validation of NGcGM3 ganglioside as a new target for cancer immunotherapy. Expert Opin Biol Ther. 2010;10(2):153-62. 75. Labrada M. Induction of leukocyte infiltration at metastatic site mediates the protective effect of NGcGM3-based vaccine. Human Vaccines and Immunotherapeutics. En prensa 2014. 76. Akashi Y, Okamoto I, Iwasa T, Yoshida T, Suzuki M, Hatashita E, Yamada Y, Satoh T, Fukuoka M, Ono K, Nakagawa K. Enhancement of the antitumor activity of ionising radiation by Nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status. Br J Cancer 2008;98:749-55. 77. Carr A, Rodríguez E, Arango MC, Camacho R, Osorio M, Gabri M, et al. Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine. J Clin Oncol. 2003;21(6):1015-21. 78. Registro Clínico. Inmunoterapia activa específica con la vacuna NGcGM3/VSSP/Montanide ISA 51 en pacientes con cáncer de mama metastásico. Fase II. Disponible en: http://registroclinico.sld.cu/en/trials/RPCEC00000068-En 79. De la Torre A, Hernández J, Ortiz R, Cepeda M, Pérez K, Car A, et al. NGlycolylGM3/VSSP vaccine in metastatic breast cancer patients: results of Phase I/IIa clinical trial. Breast Cancer (Auckl). 2012;6:151-7. 80. Osorio M, Gracia E, Reigosa E, Hernández J, de la Torre A, Saurez G, et al. Effect of vaccination with N-glycolyl GM3/VSSP vaccine by subcutaneous injection in patients with advanced cutaneous melanoma. Cancer Manaq Res. 2012;4:341-5. 81. Pérez R., Betsholtz C., Westermark B. Frequent expression of growth factors for messenquimal cells in human mamary carcinoma cell lines. Cancer Research 1987; 47, 3425-3429. 82. Dobashi Y., Stren DF., Membrane anchored form of EGF stimulate focus formation and intercellular comunication. Oncogene. 1991; 6:1151-1159. 83. Crombet T, Osorio M, Cruz T, Roca C, del Castillo R, Mon R, Iznaga-Escobar N, Figueredo R, Koropatnick J, Renginfo E, Fernandez E, Alvarez D, et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 2004;22:1646-54. 84. Verduzco-Rodriguez L, Aguirre-Gonzalez EH, Verduzco-Aguirre HC. Durable complete response induced by paclitaxel-nimotuzumab-methotrexate chemotherapy in a patient with metastatic head and neck squamous cell carcinoma. Hematol Oncol Stem Cell Ther 2011;4:182-4. 85. Basavaraj C, Sierra P, Shivu J, Melarkode R, Montero E, Nair P. Nimotuzumab with chemoradiation confers survival advantage in treatment naive head and neck tumors overexpressing EGFR. Cancer Biol Ther 2010;10. 86. Crombet T. Use the humanized anti-EGFR MAb (nimotuzumab) and radiotherapy for the treatment of high grade glioma patients European Journal of Cancer, suppl 2008 6:168. 87. Crombet T, Cabanas R, Alert J, et al. Nimotuzumab and radiotherapy in children and adolescents with brain stem glioma: preliminary results from a phase II study Eur J Cancer Suppl 2009;7 88. Ramos-Suzarte M, Lorenzo-Luaces P, Lazo NG, et al. Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy. Cancer Biol Ther 2012;13:600-5. 89. Strumberg D, Schultheis B, Scheulen ME, et al. Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. Invest New Drugs 2010. 90. Macias A, Neninger E, Santiesteban E, et al. Preliminary results of a phase II clinical trial of the anti EGFR monoclonal antibody Nimotuzumab in combination with whole brain radiation therapy in patients diagnosed with advanced non-small cell lung cancer tumors unresectable brain metastases. Eur J Cancer 2008;Suppl:160-1. 91. Crombet T, Osorio M, Cruz T, Roca C, del Castillo R, Mon R, Iznaga-Escobar N, Figueredo R, Koropatnick J, Renginfo E, Fernandez E, Alvarez D, et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 2004;22:1646-54. 92. Clinical Study Report Protocol Number YMB1000/004 “An Open Phase I Dose Escalation Study to Assess the Safety of TheraCIM-hR3 (Ymb1000), (h-R3) in Conjunction with Radiotherapy in Patients with Advanced (Unresectable) Squamous Cell Carcinoma of the Head and Neck Who are Suitable for Radiotherapy”. June 27, 2007. 93. Rodriguez MO, Rivero TC, Bahi RD, Muchuli CR, Bilbao MA, Vinageras EN, et al. Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of de head and neck. Cancer Biology & Therapy, 2010; 9(5):343-349. 94. Ramakrishnan MS, Eswaraiah A, Crombet- Ramos T, Piedra p y col. Nimotuzumab, a promising therapeutic monoclonal antibody for treatment of tumors of epitelial origin. mAbs 1:1, 41-48;january/feruary 2009. 95. Solomon MT, Selva JC, Figueredo J, et al. Radiotherapy plus the anti-EGFR mAb nimotuzumab or placebo for the treatment of high-grade glioma patients. J Clin Oncol 2012;30. 96. Custodio A.; Mendez M.; ProvencioM. Targeted therapies for advanced non-small-cell lung cancer: Current status and future implications. Cancer Treatment Reviews .2012,38, 36–53. 97. Bebb, G.; Smith, C.; Rorke, S.; Boland, W.; Nicacio, L.; Sukhoo, R.; Brade, A. Phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy. Cancer Chemother.Pharmacol.2010, 67, 837-45. 98. Choi, H.J.; Sohn, J.H.; Lee, C.G.; Shim, H.S.; Lee, I.; Yang, W.I.; Kwon, J.E.; Kim, S.K.; Park, M.; Lee, J.H.; et al. A phase I study of nimotuzumab in combination with radiotherapy in stagesIIB-IV non-small cell lung cancer unsuitable for radical therapy: Korean results. LungCancer.2011, 71, 55-59. 99. Macías A. et al. Uso del AcM hR3 y radioterapia en el tratamiento de pacientes con cáncer de pulmón de células no pequeñas (CPCNP) portadores de metástasis cerebral. IIC RD-EC079. Informe Final.2010. 100. Crombet T. et al. Programa Uso Clínico Expandido. Evaluación de la supervivencia de pacientes con tumores avanzados de pulmón de células no pequeñas tratados con el anticuerpo monoclonal anti-EGFR nimotuzumab. Informe Final.2010. 101. Lee M. Ellis et al: American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes. JCO 32 (12):1277- 1280, 2014.